Skip to main content

Table 1 Baseline clinical characteristics of the training and validation cohort

From: Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

 

Total (n = 151)

Training (n = 103)

Validation (n = 48)

P values

Age(years), median (IQR)

58.0 (51.0, 67.0)

61.0 (50.3, 68.0)

56.0 (51.0, 64.0)

0.307

Gender, no.(%)

   

0.355

 Male

119 (78.8)

79 (76.7)

40 (83.3)

 

 Female

32 (21.2)

24 (23.3)

8(16.7)

 

ALT, (U/L), median (IQR)

33.5 (20.8, 47.8)

29.70 (20.7, 45.3)

35.4 (20.9, 52.9)

0.220

AST, (U/L), median (IQR)

33.0 (24.4, 44.1)

32.4 (24.5, 43.4)

33.9 (24.0, 49.8)

0.407

GGT, (U/L), median (IQR)

50.8 (29.2, 108.8)

49.6 (30.2, 92.7)

52.1 (27.9, 144.5)

0.771

AFP, (µg/L), median(IQR)

15.3 (3.1, 417.5)

15.5 (3.1, 527.4)

11.6 (2.9, 301.6)

0.718

AFP group.no(%)

   

0.555

 ≤ 20 µg/L

79 (52.3)

54 (52.4)

25 (52.1)

 

 20–400 µg/L

34 (22.5)

21 (20.4)

13 (27.1)

 

 > 400 µg/L

38 (25.2)

28 (27.2)

10 (20.8)

 

Hepatitis B, no.(%)

   

0.856

 Negative

36 (23.8)

25 (24.3)

11 (22.9)

 

 Positive

115 (76.2)

78 (75.7)

37 (77.1)

 

Hepatitis C, no.(%)

   

1.000

 Negative

145 (96.0)

99 (96.1)

46 (95.8)

 

 Positive

6 (4.0)

4 (3.9)

2 (4.2)

 

Cirrhosis, no.(%)

   

0.520

 Negative

43 (28.5)

31 (30.1)

12 (25.0)

 

 Positive

108 (71.5)

72 (69.9)

36 (75.0)

 

Tumor grade, no.(%)

   

0.398

 Low-grade tumor

100 (66.2)

71(68.9)

29(60.4)

 

 High-grade tumor

51(33.8)

32 (31.0)

19(39.6)

 
  1. AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase